Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Lyra Therapeutics, Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 33 staff and has a market cap (total outstanding shares value) of USD$146.4 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$9.71 |
---|---|
52-week range | USD$8.98 - USD$22 |
50-day moving average | USD$10.9446 |
200-day moving average | USD$12.0254 |
Wall St. target price | USD$26 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.71 from 2020-12-18
1 week (2021-01-07) | -11.89% |
---|---|
1 month (2020-12-17) | 1.46% |
3 months (2020-10-16) | -26.10% |
6 months (2020-07-16) | -16.37% |
1 year (2020-01-13) | N/A |
---|---|
2 years (2019-01-13) | N/A |
3 years (2018-01-13) | N/A |
5 years (2016-01-13) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -51.21% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$146.4 million |
TTM: trailing 12 months
There are currently 132,149 Lyra Therapeutics shares held short by investors – that's known as Lyra Therapeutics's "short interest". This figure is 8% down from 143,584 last month.
There are a few different ways that this level of interest in shorting Lyra Therapeutics shares can be evaluated.
Lyra Therapeutics's "short interest ratio" (SIR) is the quantity of Lyra Therapeutics shares currently shorted divided by the average quantity of Lyra Therapeutics shares traded daily (recently around 102441.08527132). Lyra Therapeutics's SIR currently stands at 1.29. In other words for every 100,000 Lyra Therapeutics shares traded daily on the market, roughly 1290 shares are currently held short.
However Lyra Therapeutics's short interest can also be evaluated against the total number of Lyra Therapeutics shares, or, against the total number of tradable Lyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyra Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lyra Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0234% of the tradable shares (for every 100,000 tradable Lyra Therapeutics shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyra Therapeutics.
Find out more about how you can short Lyra Therapeutics stock.
We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.